和元生物收盘上涨2.07%，最新市净率1.89，总市值35.24亿元

Company Overview - He Yuan Biological Technology (Shanghai) Co., Ltd. focuses on the gene therapy field, providing CRO services for basic research and CDMO services for drug development [1] - The company offers products including gene therapy CRO, gene therapy CDMO, biological agents, and reagents [1] Financial Performance - For the third quarter of 2024, the company reported revenue of 184 million yuan, a year-on-year increase of 34.22% [1] - The net profit for the same period was -189.77 million yuan, representing a year-on-year decline of 166.90% [1] - The sales gross margin was -21.95% [1] Market Position - As of the third quarter of 2024, 40 institutions hold shares in He Yuan Biological, with a total holding of 6.84 million shares valued at 34 million yuan [1] - The company's latest closing price was 5.43 yuan, with a market capitalization of 3.524 billion yuan and a price-to-book ratio of 1.89 [1] Industry Comparison - The average PE (TTM) for the industry is 46.28, while He Yuan Biological has a PE (TTM) of -10.84 [2] - The industry median PE (TTM) is 47.68, indicating that He Yuan Biological is significantly below industry averages [2]